![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Releases New Guidance for ADHD Generic
FDA Releases New Guidance for ADHD Generic
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
The FDA issued new product-specific draft guidance for generic methylphenidate oral extended-release tablets.
The guidance outlines the agency’s preferred design of bioequivalence studies to support ANDAs.
Methylphenidate HCl was initially approved as a new drug in 1982, and has been marketed as Ritalin, Concerta and several other brand names. It is used to treat attention deficit hyperactivity disorder.
Upcoming Events
-
21Oct